Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nancy M Allen LaPointe

Showing results (11-20 of 62) with videos related to

Pageof 7
Sort By:
The American Journal of Cardiology|April 9, 2008
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospitalNancy M Allen Lapointe, Jie-Lena Sun, Sigal Kaplan, et al.
Pharmacogenomics|December 11, 2014
Pilot study: incorporation of pharmacogenetic testing in medication therapy management servicesSusanne B Haga, Nancy M Allen LaPointe, Jivan Moaddeb, et al.
The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.
American Heart Journal|November 5, 2003
Evaluation of the dofetilide risk-management programNancy M Allen LaPointe, Anita Chen, Bradley Hammill, et al.
American Heart Journal|November 2, 2013
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillationNancy M Allen LaPointe, Yuliya Lokhnygina, Gillian D Sanders, et al.
The Annals of Pharmacotherapy|July 2, 2009
Use of beta-blockers in patients with an implantable cardioverter defibrillatorNancy M Allen LaPointe, Judith A Stafford, Paul A Pappas, et al.
The American Journal of Cardiology|December 11, 2014
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart diseaseNancy M Allen LaPointe, Dadi Dai, Laine Thomas, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|August 13, 2008
Development and evaluation of an improved methodology for assessing adherence to evidence-based drug therapy guidelines using claims dataKensaku Kawamoto, Nancy M Allen LaPointe, Garry M Silvey, et al.
Circulation. Cardiovascular Quality and Outcomes|April 2, 2015
Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugsNancy M Allen LaPointe, David Dai, Laine Thomas, et al.
The American Journal of Cardiology|May 26, 2009
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery diseaseNancy M Allen LaPointe, Yi Zhou, Judith A Stafford, et al.
Pageof 7

Showing results (11-20 of 62) with videos related to

Sort By:
Pageof 7
The American Journal of Cardiology|April 9, 2008
Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospitalNancy M Allen Lapointe, Jie-Lena Sun, Sigal Kaplan, et al.
Pharmacogenomics|December 11, 2014
Pilot study: incorporation of pharmacogenetic testing in medication therapy management servicesSusanne B Haga, Nancy M Allen LaPointe, Jivan Moaddeb, et al.
The American Journal of Medicine|January 13, 2004
Economic effects of beta-blocker therapy in patients with heart failurePatricia A Cowper, Elizabeth R DeLong, David J Whellan, et al.
American Heart Journal|November 5, 2003
Evaluation of the dofetilide risk-management programNancy M Allen LaPointe, Anita Chen, Bradley Hammill, et al.
American Heart Journal|November 2, 2013
Adherence to guideline recommendations for antiarrhythmic drugs in atrial fibrillationNancy M Allen LaPointe, Yuliya Lokhnygina, Gillian D Sanders, et al.
The Annals of Pharmacotherapy|July 2, 2009
Use of beta-blockers in patients with an implantable cardioverter defibrillatorNancy M Allen LaPointe, Judith A Stafford, Paul A Pappas, et al.
The American Journal of Cardiology|December 11, 2014
Antiarrhythmic drug use in patients <65 years with atrial fibrillation and without structural heart diseaseNancy M Allen LaPointe, Dadi Dai, Laine Thomas, et al.
AMIA ... Annual Symposium Proceedings. AMIA Symposium|August 13, 2008
Development and evaluation of an improved methodology for assessing adherence to evidence-based drug therapy guidelines using claims dataKensaku Kawamoto, Nancy M Allen LaPointe, Garry M Silvey, et al.
Circulation. Cardiovascular Quality and Outcomes|April 2, 2015
Comparisons of hospitalization rates among younger atrial fibrillation patients receiving different antiarrhythmic drugsNancy M Allen LaPointe, David Dai, Laine Thomas, et al.
The American Journal of Cardiology|May 26, 2009
Association between mortality and persistent use of beta blockers and angiotensin-converting enzyme inhibitors in patients with left ventricular systolic dysfunction and coronary artery diseaseNancy M Allen LaPointe, Yi Zhou, Judith A Stafford, et al.
Pageof 7